西罗莫司片怎么样？

It was approved for marketing in China in 2002, bringing new options for the treatment of domestic patients. Sirolimus tablets are an immunosuppressant that inhibits the activation and proliferation of T lymphocytes by inhibiting their response to stimulation by antigens and cytokines (IL-2, IL-4 and IL-15). Let’s learn more about Biocon India’s sirolimus tablets?

Sirolimus combined with low-dose cyclosporine A is a better immunosuppressive treatment option after renal transplantation, and the use of sirolimus can reduce the dose of CNI. It is safe and effective to control the steady-state trough concentration of sirolimus at 4-8ng/ml or 5-8ng/ml after renal transplantation. Sirolimus also reduces the incidence of non-melanoma skin cancer after kidney transplantation. In addition, sirolimus has also achieved good anti-rejection effects after transplantation such as heart transplantation, lung transplantation, and corneal transplantation, but the therapeutic concentration has not been reported.

It can be seen that the use of sirolimus in kidney transplant patients can not only effectively reduce the risk of rejection, but is also relatively safe. However, immunosuppression may also increase the risk of infection, including activation of latent viral infections, fatal infections, and sepsis. Patients need to take relevant precautions, including preventive treatment of Pneumocystis jiroveci pneumonia (PCP) 1 year after transplantation, and prevention of cytomegalovirus (CMV) 3 months after transplantation.

Biocon is one of India's three largest biotech companies and an emerging global biopharmaceutical company that is committed to reducing the cost of treatment for chronic diseases such as diabetes, cancer and autoimmune disease patients by leveraging India's cost advantages and partners to provide affordable healthcare solutions to healthcare systems around the world.

Clinically, it is mainly used to prevent rejection of kidney transplants. It does not inhibit calcineurin after binding to cytoplasmic proteins, so it can completely avoid the nephrotoxicity of calcineurin inhibitors (CNI). It is one of the best choices when liver or renal insufficiency occurs after organ transplantation or when CNI cannot reach the ideal drug concentration.